Go back to News
NEWS
Miguel Troncoso in CGAE article on the EU case against AstraZeneca
Miguel Troncoso, managing partner of the Brussels office of Gómez-Acebo & Pombo and expert in competition law and State aid, has contributed to the article published on the website of the General Council of Spanish Lawyers. delves into the EU’s demand aimed at securing doses contracted to the pharmaceutical company AstraZeneca, rather than receiving compensation. According to Troncoso’s opinion, “the supply contract does not provide for contractual penalties or compensation in favour of the EU in the event of non-compliance, at least in the version that has been made public. Therefore, the lawsuit is aimed at obliging AstraZeneca to supply the vaccines in the agreed quantity and on time”.
In addition, it should be noted that “the version of the contract that has come to light is not complete, since confidential information or AstraZeneca’s business secrets have been concealed,” Troncoso points out. As the company maintains, the contract was signed on the basis of what is known as “best efforts”, that is to say, that it was committed to doing “everything possible” to comply with the agreement. This undertaking was affected, according to AstraZeneca, first by a storm at the end of January that affected the production line at its factory in Wales, and subsequently by the suspension of vaccination in many countries after side effects were detected in some people receiving the vaccine.
Read the full article here
In addition, it should be noted that “the version of the contract that has come to light is not complete, since confidential information or AstraZeneca’s business secrets have been concealed,” Troncoso points out. As the company maintains, the contract was signed on the basis of what is known as “best efforts”, that is to say, that it was committed to doing “everything possible” to comply with the agreement. This undertaking was affected, according to AstraZeneca, first by a storm at the end of January that affected the production line at its factory in Wales, and subsequently by the suspension of vaccination in many countries after side effects were detected in some people receiving the vaccine.
Read the full article here
Lawyer mentioned
Miguel Troncoso – Partner
Press contact
Sandra Cuesta
Director of Business Development, Marketing and Communications
Sandra Cuesta
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
PUBLICATION
One week ago
Claim assignment and assignment of right to rescind underlying contract
There is no single answer to the question of whether or not the assignee of a claim has the power to rescind the underlying contract when the assigned debtor defaults. As a general rule, such rescission will not be possible for the assignee.
PUBLICATION
16 Jul, 2026
New EU regulation on the screening of foreign investments
Regulation (EU) 2026/1386 establishes a harmonised and mandatory framework for the screening of foreign investments in the Union and replaces the previous Regulation (EU) 2019/452. Among its most notable new features are the obligation for all Member States to have a national screening mechanism with harmonised minimum requirements; the inclusion within its scope of investments made by European subsidiaries controlled by third-country investors; the implementation of a two-stage national procedure; and the strengthening of the European cooperation mechanism through a risk-screening system and a more stringent “comply or explain” principle.
Finally, the paper analyses the regulation’s impact on Spain, whose current review mechanism must be adapted in areas such as procedural structure, the review of completed transactions, sectoral expansion, and the penalty regime by 17 January 2028.
PUBLICATION
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
18 Jun, 2026
Royal Decree 415/2026: key aspects of the new health technology assessment system
Royal Decree 415/2026 establishes a unified framework for the assessment of health technologies in Spain, distinguishing between the technical assessment and the administrative decision regarding funding, pricing or inclusion in the service catalogue, and incorporating the requirements of Regulation (EU) 2021/2282. The aspect that raises the most legal questions in this new piece of legislation is the connection between the assessment regulated by the Royal Decree and the procedures for funding, pricing, and inclusion in the service catalogue.
PUBLICATION
09 Jun, 2026
Partial limitation defences that may be raised in relation to the limitation period within a cartel (Supreme Court Judgment no. 681/2026 of 6 May)
A flawed judgment on a problem that has remained unresolved to date in the truck cartel. The issue is not whether the liability-in-solidum regime applies, but whether co-liable parties can raise personal defences.
PUBLICATION
04 Jun, 2026
Unanimous shareholders' agreements and dividends in specie
The Supreme Court and the Madrid Provincial Court, following established legal doctrine, have reiterated that a party to a unanimous shareholders’ agreement acts in bad faith if he or she challenges a company resolution passed in compliance with said shareholders’ agreement. In this case, the shareholders’ agreement provided for the possibility of paying dividends in kind, and the contested resolution — which was passed by a majority at the shareholders’ meeting — transferred certain real estate properties to one of the shareholders (with his consent) in payment of the dividend due to him.
PUBLICATION
27 May, 2026
An action for declaration of invalidity of an already-terminated franchise agreement is admissible
An action for declaration of invalidity of an agreement can almost always be brought, even if the agreement has been performed and terminated.
PUBLICATION
30 Apr, 2026
Pharma & Healthcare No. 48
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
06 Mar, 2026
The long arm of the Unified Patent Court based on the "event giving rise to the infringement" and considerations on the application of lex loci protectionis
This paper analyses the decision of the Mannheim Local Division of 2 October 2025, where the Unified Patent Court (UPC) justifies its jurisdiction on the basis of shipment of products from a UPC territory by company listed as authorized representative in the EC and UK markets as event giving rise to damage. Furthermore, although the applicable law with regard to the infringement of the European patent validated in States that are not party to the Agreement on a Unified Patent Court is the national law of those States, with regard to the scope of patent protection, the UPC imposes on the defendant—unduly—the burden of proving the specifics of national law.